Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
Human immunodeficiency virus (HIV) infection can bring about total collapse of the immune system by infecting helper T lymphocytes which express CD4, the molecule which mediates interaction between the cell surface and viral envelope glycoprotein gp120 (refs 3-10). HIV apparently escapes the effects of neutralizing antibodies in vivo by generating new variants which must still interact with CD4 to maintain a cycle of infection. One route to block HIV infection, therefore, could use solubilized CD4 protein to inhibit attachment of the virus to its target cell. We have used recombinant DNA techniques to generate soluble forms of CD4, and show here that these are potent inhibitors of HIV infection in vitro.
Traunecker
A
A
Basel Institute for Immunology, Switzerland.
Lüke
W
W
Karjalainen
K
K
D000818:Animals; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism*; D001667:Binding, Competitive; D002460:Cell Line; D003588:Cytopathogenic Effect, Viral; D006678:HIV / Q000502:physiology*; D015699:HIV Envelope Protein gp120; D015728:Receptors, HIV; D011991:Receptors, Virus / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000378:metabolism / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology*; D012191:Retroviridae Proteins / Q000378:metabolism; D012995:Solubility
D000945:Antigens, Differentiation, T-Lymphocyte; D015699:HIV Envelope Protein gp120; D015728:Receptors, HIV; D011991:Receptors, Virus; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D012191:Retroviridae Proteins